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Exosomes from metastatic cancer 
cells transfer amoeboid phenotype 
to non-metastatic cells and 
increase endothelial permeability: 
their emerging role in tumor 
heterogeneity
Odessa Schillaci1, Simona Fontana  1, Francesca Monteleone1, Simona Taverna2, Maria 
Antonietta Di Bella1, Dolores Di Vizio3 & Riccardo Alessandro1,2
The goal of this study was to understand if exosomes derived from high-metastatic cells may influence 
the behavior of less aggressive cancer cells and the properties of the endothelium. We found that 
metastatic colon cancer cells are able to transfer their amoeboid phenotype to isogenic primary cancer 
cells through exosomes, and that this morphological transition is associated with the acquisition of 
a more aggressive behavior. Moreover, exosomes from the metastatic line (SW620Exos) exhibited 
higher ability to cause endothelial hyperpermeability than exosomes from the non metastatic line 
(SW480Exos). SWATH-based quantitative proteomic analysis highlighted that SW620Exos are 
significantly enriched in cytoskeletal-associated proteins including proteins activating the RhoA/
ROCK pathway, known to induce amoeboid properties and destabilization of endothelial junctions. In 
particular, thrombin was identified as a key mediator of the effects induced by SW620Exos in target 
cells, in which we also found a significant increase of RhoA activity. Overall, our results demonstrate 
that in a heterogeneous context exosomes released by aggressive sub-clones can contribute to 
accelerate tumor progression by spreading malignant properties that affect both the tumor cell 
plasticity and the endothelial cell behavior.
Human tumors display a significant intratumor heterogeneity that influences their metastatic potential and ther-
apeutic resistance. Tumor heterogeneity is mainly the result of genetic instability. However, the behavior of indi-
vidual tumor cells can be further increased by epigenetic alterations, which are key factors in the formation of 
the tumor initiating cancer cell subpopulations1, 2. Intravital microscopy techniques, in a cancer living mouse 
model, have shown that the existence of few individual cells with aggressive molecular features within a tumor 
is sufficient to support cancer progression3. Over recent years, a growing number of studies suggest that the 
tumor microenvironment (TME), which contributes to a functional crosstalk between different cell types, plays 
an important role in determining the heterogeneity observed within and across tumors4. This has resulted in an 
increased understanding of the crosstalk that occurs between malignant cells and their microenvironment5–10. 
However, a number of major questions remain unanswered, underscoring the need to better characterize the 
steps of tumor progression, and thereby to identify new and effective ways of treating metastatic disease. Our 
group and others have demonstrated that cancer cells release oncogenic cargo in exosomes, which play a crucial 
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role in the crosstalk between cells and TME11–14. Exosomes are nanometer-sized vesicles (40–100 nm diameter) 
of endocytic origin that are released by different cell types under both normal and pathological conditions. They 
function as cell free messengers that could potentially affect tumor heterogeneity15, due to the nature of the mol-
ecules (proteins, mRNAs, miRNAs and lipids) that they transport. Tumor cells actively shed exosomes into their 
surrounding microenvironment and these vesicles have pleiotropic functions in the regulation of tumor growth 
and progression, immune escape, tumor invasion, neovascularization, and metastasis16. In addition to effects 
exerted within the primary TME, tumor-derived exosomes (TDEs) play a crucial role in the establishment of the 
pre-metastatic niche16 by preparing lymph-node and new secondary sites for metastases14. TDEs can stimulate 
the secretion of growth factors, cytokines and angiopoietic factors by stroma cells, induce the proliferation of 
endothelial cells, thus promoting angiogenesis and metastasis in other organs12, 17. However, if and how TDEs can 
affect cell plasticity in the heterogeneous context of the primary tumor, thus spreading aggressive phenotype to 
less aggressive tumor cells and functionally affecting other components of the TME has not been elucidated yet.
Here, we demonstrate that exosomes derived from cells with high metastatic potential can modulate pheno-
typic plasticity in less aggressive cancer cells and elicit structural alterations of endothelial cells in a RhoA/ROCK 
dependent fashion. This ultimately contributes to create a permissive microenvironment for tumor dissemination.
Results
Characterization of SW480 and SW620-cell derived exosomes. SW480 and SW620 cell-derived 
exosomes (SW480Exos and SW620Exos) were purified by flotation in discontinuous 5–60% density centrifuga-
tion gradients (OptiprepTM) and characterized by dynamic light scattering (DLS) analysis and western blotting 
(Fig. 1). CD63 and CD81, typically enriched in exosomes18, were enriched in 1.10 g/ml and 1.15 g/ml buoyant 
density fractions, obtained from the gradient fraction derived from the 100,000 × g pellets (Fig. 1A). Moreover, 
Calnexin, a ubiquitous ER protein, was exclusively found in whole lysate fractions (Fig. 1B). The DLS analysis 
revealed an average hydrodynamic diameter of about 40 nm for both types of exosomes (Fig. 1C). Collectively, 
these results show that EVs from SW cells are in the size range of exosomes and express exosome markers.
Exosomes released by metastatic cells affect morphological and functional properties of 
non-metastatic tumor cells. SW480 and SW620 cells exhibit different features in culture. In line with 
published data19, our scanning electron microscopy analysis (Fig. 2A,B) indicates that SW480 cells display an 
elongated morphology (Fig. 2A and confocal analysis in Fig. 2C), whereas SW620 cells appear almost exclusively 
round (Fig. 2B) with evident membrane blebbing typical of an amoeboid phenotype20 (Fig. 2D). By labeling 
exosomes with PKH26, we observed that SW480 and SW620 cells were able to internalize exosomes after 3 hrs 
of incubation at 37 °C (Fig. 2E,F and Supplementary Fig. S1). Interestingly, SW620Exos were able to transfer the 
Figure 1. SW480 and SW620 cell-derived exosomes characterization. (A) Equal amount (15 µg) of SW480Exo 
and SW620Exo proteins were probed with the indicated antibodies that detect exosome-enriched proteins. 
Original uncropped WBs are reported in Figure S7A. (B) 30 µg of both SW480Exos and SW620Exos and 
cellular lysates were incubated with anti-calnexin to exclude cellular contamination in exosome preparation. 
Original uncropped WBs are reported in Figure S7B. WCL: Whole Cell Lysate; EXOs: exosomes. (C) Dynamic 
light scattering (DLS) analysis of SW480Exos and SW620Exos. Results were plotted as a % mass distribution in 
order to accurately represent the size distribution of the biological sample.
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amoeboid phenotype of the originating cells (Fig. 2D) to SW480 cells (Fig. 2F), inducing a significant increase 
of the percentage of blebbing cells in this otherwise mesenchymal-like line (Fig. 2G); conversely, the treatment 
of SW480 cells with their own exosomes did not result in phenotypic changes (Fig. 2E). Furthermore, while 
SW480Exos did not induce any change in the morphology of SW620 cells, treatment of these cells with homol-
ogous exosomes (SW620Exos) induced a propagation of amoeboid features (Supplementary Fig. S1). In order 
to exclude the possibility that SW620Exos-induced blebbing was due to apoptosis, we performed a caspase 3/7 
enzymatic activity assay that demonstrated that SW620Exo treatment does not induce apoptosis in SW480 
recipient cells (Supplementary Fig. S2). Finally, because amoeboid membrane blebbing is considered as a mor-
phological feature that is typically associated to rapid motility, which helps cancer cells to quickly migrate in 
different environments21, we tested if the transition of SW480 cells to an amoeboid phenotype coincided with the 
acquisition of a more aggressive behavior. As shown in Fig. 3 we found that SW620Exos significantly increased, 
both migration (Fig. 3A) and invasion (Fig. 3B) of non-metastatic cells in a dose-dependent manner. Overall, 
these results indicate that metastatic cells can transfer their round/amoeboid phenotype to non-amoeboid cancer 
cells via exosomes and that this morphological transition is associated with the acquisition of a more aggressive 
behavior. The ability of exosomes released by metastatic cells to transfer a biological and functional phenotype 
was also confirmed on other non-metastatic colon cancer cells. We found that SW620Exos, but not SW480Exos 
induced membrane bleb formation and a significant increase of motile and invasive properties also in Caco2 cells 
(Fig. 4A–C).
Exosomes derived from cancer cells with different aggressive propensities differentially affect 
the properties of endothelial cells. Tumor progression is a multistep process due not only to the intrinsic 
capabilities acquired by tumor cells themselves, but also to their interaction with different components of the 
tumor microenvironment. In order to understand if exosomes derived from cells with different aggressive pro-
pensities can differentially affect cells in the microenvironment, thus contributing to accelerate tumor dissemina-
tion, we evaluated the effects of SW480Exos and SW620Exos on the endothelium, by using HUVECs as in vitro 
model. While the ability of HUVECs to internalize SW480Exos and SW620Exos was comparable (Supplementary 
Fig. S3A), the effects induced by the two populations of exosomes were markedly different. Figure 5A shows that 
treatment with 20 µg/ml of SW620Exos for 6 hrs affected the integrity of endothelial monolayers resulting in an 
Figure 2. Exosomes released by metastatic cells affect morphological properties of less aggressive tumor cells. 
Scanning electron microscopy shows the spreading-elongated morphology of SW480 (A) and the round-
blebbed morphology of SW620 cells (B). Confocal micrographs display the different morphology between 
elongated SW480 (C) and amoeboid SW620 cells (D) characterized by membrane blebbling (highlighted by 
magnification). (E,F) SW480 cells treated for 3 hrs with 20 µg/ml of PKH26-labeled SW480Exos  
(E) and SW620Exos (F). Exosomes are visible as red dots inside cells. Magnification highlights round cells with 
membrane blebs in SW480 cells after treatment with SW620Exos. Both SW480 and SW620 cells were stained 
with Actin green (green); nuclear counterstaining was performed using Hoescht (blue). (G) Percentage of 
blebbing cells after exosome treatment and in control condition. The percentage of blebbing cells was obtained 
by counting 10 different fields for each condition. Values are the mean ± SD of three independent experiments. 
Significant differences were calculated in comparison to no-treated SW480 cells: *p ≤ 0.05.
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evident cell leakiness due to the loss of cell-cell contacts, while SW480Exos, used at the same dose and for the 
same time, caused just a mild alteration of endothelial cell monolayers.
In order to further evaluate the influence of SW620Exos on monolayer integrity we performed an endothelial 
permeability assay using FITC-dextran molecules. We found that treatment with SW620Exos significantly ele-
vated HUVEC monolayer permeability compared to both the control and the SW480Exo treatment condition 
(Fig. 5B).
Since it is well known that the regulation of VE-cadherin localization is essential for the endothelial barrier 
integrity and function22, we hypothesized that SW620Exos may regulate the endothelial permeability by chang-
ing the expression and/or the localization of VE-cadherin in HUVECs. Our results showed that in comparison 
to the SW480Exo treatment and the control condition, SW620Exos did not affect the VE-cadherin expression 
at both mRNA (Supplementary Fig. S3B) and protein level (Supplementary Fig. S3C), but rather induced a 
clear cytosolic delocalization of the protein, such as of other adherens junction (AJ) proteins, β-catenin and 
p120-catenin (Fig. 5C). Moreover, we noted that both exosome populations had a comparable positive effect on 
the ability of HUVECs to form vessel-like structures at least when used at a dose of 10 µg/ml, indicating that both 
aggressive and less aggressive cancer cells are able to induce angiogenesis through exosome shedding. However, 
when a higher dose of exosomes (20 µg/ml) was used, we observed that SW480Exos maintained their angiogenic 
properties, while SW620Exos lost them (Supplementary Fig. S4A,B). These results suggest that the capability of 
exosomes released by metastatic cells to destroy the endothelium integrity overcomes their angiogenic activity if 
they are used above a given dose.
Collectively, the above independent assays we carried out for evaluating the effects of exosomes released by 
spindle versus amoeboid cells demonstrated that exosomes derived from amoeboid cells have a more remarkable 
ability to increase endothelial permeability. Altogether, these results suggest that inside a heterogeneous tumor 
mass, different cell sub-populations may differentially support tumor progression through their exosomes, some 
promoting the formation of new vessels and others inducing endothelial cell leakiness, both indispensable steps 
of metastatic cascade.
Comparative proteomic analysis of SW480Exos and SW620Exos. The peptide mixtures obtained 
after trypsin digestion of three independent SW480Exo (SW480Exo_A, SW480Exo_B, SW480Exo_C) and 
SW620Exo (SW620Exo_A, SW620Exo_B, SW620Exo_C) preparations were run independently using a 
Figure 3. Exosomes released by metastatic cells enhance motile and invasive properties of less aggressive 
tumor cells. Transwell migration (A) and invasion (B) assay of SW480 cells treated with increasing doses (20 
or 50 µg/ml) of SW480Exos or SW620Exos. Representative micrographs (upper panel) and quantitative data 
(lower panel) are reported for each assay. Ctrl (Control): SW480 cells without exosome treatment. Values 
reported in the graphs are the mean ± SD of 5 fields in three independent experiments. Statistical significance 
was calculated vs ctrl and between the same doses of SW480Exos and SW620Exos as indicated by the horizontal 
lines; *p ≤ 0.05, **p ≤ 0.01.
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Data-Dependent Acquisition (DDA) method. Then, in order to build the spectral library needed for the following 
SWATH quantitation, all six DDA data sets were integrated. After searching against the Homo sapiens UniProt 
fasta database by using ProteinPilot 4.5 at a 1% critical false discovery rate (FDR), at both protein and peptide 
levels, we identified 489 proteins. More than 60% of the proteins were identified based on at least three peptides; 
proteins were called also with only one peptide but only if this peptide had high confidence (95%) and at least 9 
amino acids; the list of identified proteins is shown in Supplementary Tables, Sheet “Identification MS data”.
In order to assess the quality of our exosome preparations we performed a bioinformatic comparison between 
our protein dataset and the exosomal protein dataset deposited in the Vesiclepedia database (http://www.microve-
sicles.org/) by using FunRich (FR), an open access stand-alone tool23. We found that more than 90% of the pro-
teins identified in our experiments had been previously described as exosomal proteins (Fig. 6A). Moreover, in 
our dataset 9 out of the Top 10 exosomal proteins were present (Fig. 6A). Additionally, even if not detected by 
proteomic analysis, the presence of CD63 was shown in both SW480 and SW620 exosomes (SW-Exos) by western 
blotting (Fig. 1A). To further characterize the protein content of SW-Exos we also performed a Gene Ontology 
(GO) enrichment analysis using the FunRich database as a reference. This analysis highlighted that on the Cellular 
Component (CC) term exosomal proteins were the most significantly overrepresented in our dataset, together 
with lysosome, centrosome, cytoplasm, mitochondria and nucleus proteins; for the Biological Process (BP), the 
identified proteins were largely involved in protein metabolism, cell growth and/or maintenance, energy pathway 
and metabolism while on Molecular Function (MF) analysis, the categories most significantly enriched were 
extracellular matrix structural constituent, structural constituent of ribosome, protease inhibitor activity, catalytic 
activity, structural constituent of cytoskeleton and complement activity (Supplementary Fig. S5). Interestingly, 
these functional classes overlapped with those already described as enriched in other types of TDEs24.
In an attempt to highlight differences in protein content between exosomes released by non-metastatic and 
metastatic cells, we applied the SWATH strategy to quantify proteins content of SW480Exos and SW620Exos. 
Following ion extraction, peak alignment and normalization were performed using Peakview 2.2 software and 
the above reference spectral library, resulting in quantitative information for 414 proteins (Supplementary Tables, 
Sheet “Quantitative MS data”).
To identify differentially expressed proteins, a t-test analysis was applied, and fold-changes and p-values 
were used to rank and filter the quantitative data. Proteins showing a fold change (FC) ≥ 1.5 in relative abun-
dance and a corrected BH p-value < 0.05 were considered differentially represented in the two populations of 
Figure 4. SW620Exos affect morphological and functional properties of Caco2. (A) Confocal micrographs 
of Caco2 cells treated or not for 6 hrs with 20 μg/ml of SW480Exos or SW620Exos. Cells were stained with 
Actin green (green) and nuclear counterstaining was performed using Hoescht (blue). (B) Percentage of Caco2 
blebbing cells after exosome treatment and in control condition. The percentage of blebbing cells was obtained 
by counting 5 different fields for each condition. (C) Transwell migration and invasion assay of Caco2 cells 
treated with 20 µg/ml of SW840Exos or SW620Exos. Representative micrographs (left panels) and quantitative 
data (right panel) are reported for each assay. Ctrl (Control): Caco2 cells without exosome treatment. Values 
reported in the graphs are the mean ± SD of 5 fields in three independent experiments. Statistical significance 
was calculated as indicated by the horizontal lines; *p ≤ 0.05, ** p ≤ 0.01, ***p ≤ 0.001.
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exosomes (Fig. 6B). In total, we found 150 proteins that were significantly differentially represented between 
the SW480Exos and SW620Exos and among them 107 were enriched and 43 were depleted in SW620Exos in 
comparison to SW480Exos (Supplementary Tables, Sheet “Quantitative MS data”). The heatmap in Fig. 6C shows 
the intensity changes of the differentially represented proteins in each biological repeat. All of the differentially 
represented proteins were functionally categorized using the FunRich software in order to identify the functional 
classes that were significantly enriched in exosomes derived from metastatic cells but not from non-metastatic 
cells. As Cellular Component (Fig. 6D), we found that 3 of the five categories enriched in SW620Exos were related 
to cytoskeletal system: Cytoskeleton (6.4 Fold in SW620 Exos vs 1 Fold in SW480Exos), microtubule (11.3 Fold 
in SW620 Exos vs 0 Fold in SW480Exos) and actin cytoskeleton (4 Fold in SW620 Exos vs 0 Fold in SW480Exos). 
Conversely, the majority of the proteins under-represented in metastatic cells-derived exosomes were assigned 
to the categories of nucleosome (0 Fold in SW620Exos vs 50.8 Fold in SW480Exos), ribonucleoprotein complex 
(0 Fold in SW620 Exos vs 41.3 Fold in SW480Exos), extracellular matrix (7.6 Fold in SW620 Exos vs 26 Fold 
in SW480Exos), ribosome (1.3 Fold in SW620 Exos vs 28 Fold in SW480Exos) and centrosome (5.5 Fold in 
SW620Exos vs 9.5 Fold in SW480Exos).
The enrichment of cytoskeletal-associated proteins in metastatic cell-derived exosomes was particularly inter-
esting because it is known that the mesenchymal to amoeboid transition as well as the alteration of endothe-
lial structure are specifically related to changes in cytoskeleton organization mediated by the activation of the 
small GTPase RhoA25, 26. Thus, we next asked if within the group of proteins over-represented in SW620Exos 
there were RhoA interactors able to induce its activation. STRING analysis performed adding RhoA to the 
dataset of proteins enriched in SW620Exos showed that this GTPase interacts with seven proteins highly rep-
resented in metastatic cells-derived exosomes (Fig. 6E). Interestingly among them, RacGAP1 (FC SW620Exos 
vs SW480Exos = 9.8, p = 6.65e-05; Supplementary Tables, Sheet “Quantitative MS data”) and F2 (Thrombin; 
FC SW620Exos vs SW480Exos = 2.25, p = 7.1e-05; Supplementary Tables, Sheet “Quantitative MS data”) are 
described as direct activators of RhoA27–30. In line with the observation that Thrombin was up-represented in 
SW620Exos, we found that the expression levels of Thrombin mRNA was significantly higher in SW620 cells than 
in SW480 cells (Supplementary Fig. S6).
Thrombin exported in SW620Exos is a novel functional mediator of intercellular communication. 
In order to validate the proteomic data and to highlight a key mediator of the phenotypic switch induced in 
target cells by SW620Exos, we treated SW480 cells with increasing doses of purified Thrombin. Confocal images 
Figure 5. Exosomes derived from cancer cells with different grade of aggressiveness differentially affect the 
properties of endothelial cells. (A) Confocal micrographs of HUVECs treated for 6 hrs with 20 μg/ml of SW480 
or SW620 cell-derived exosomes. (B) Dextran permeability assay of HUVEC monolayer. Permeability assay was 
performed by adding in the upper chamber 20 μg/ml of SW480Exos or SW620Exos and 6 hrs after determining 
FITC-Dextran fluorescence in the lower chamber. Values reported in the graph are the mean ± SD of three 
independent experiments. Statistical significance was calculated as indicated by the horizontal lines; *p ≤ 0.05. 
(C) Confocal micrographs of HUVECs treated for 6 hrs with 20 μg/ml of SW480Exos or SW620Exos show 
the localization of VE-cadherin (green), P-120 catenin (red) and β-catenin (red). Nuclear counterstaining was 
performed using Hoescht (blue). Ctrl (Control): HUVECs treated with vehicle.
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reported in Fig. 7A show that Thrombin elicited a dose-dependent phenotypic switch in SW480 cells, inducing 
a rounded morphology at the lower dose (0.2 U/ml) and a significant increasing of bleb formation at the higher 
dose (0.5 U/ml) as also reported in the graph in Fig. 7B. The transition of SW480 cells from an elongated to amoe-
boid phenotype following the treatment with thrombin perfectly mimicked the result obtained after exposure to 
SW20Exos, supporting the central role that thrombin can have in this system. Moreover, we found that when cells 
were co-treated with thrombin and Y-27632, a specific ROCK inhibitor, the mesenchymal to amoeboid transition 
induced by thrombin was reverted, strongly suggesting that this effect was mediated by activation of the RhoA/
ROCK pathway.
Similarly, we observed that Thrombin induced a remarkable monolayer alteration and a significant increase 
of endothelial permeability, comparable to that elicited by SW620Exos, in HUVECs (Fig. 7C,D). These effects 
were reverted when HUVECs were co-treated with thrombin and Y-27632 (Fig 7C,D), again supporting the 
involvement of the RhoA/ROCK pathway in this process. Our observations support previous reports on 
thrombin-induced modulation of endothelium permeability mediated by RhoA activation31.
SW620Exos activate the RhoA/Rock pathway in recipient cells. In light of the data emerging 
from the proteomic analysis and evaluating the effects induced by Thrombin treatment on SW480 cells, we 
wanted to determine if exosomes released by metastatic cells affected the activity of RhoA/Rock signaling 
pathway in recipient cells. By using the G-LISA RhoA Activation Biochem assay kit, we observed that in 
both SW480 cells and HUVECs, SW620Exos elicited increased RhoA activity compared with vehicle-treated 
cells, as demonstrated by a higher amount of RhoA coupled to GTP (Fig. 8A). Levels of active RhoA in 
SW620Exo-treated cells did not correspond to the levels of total RhoA, and this result was reproduced multiple 
times (Fig. 8A). Moreover, in SW480 cells treated with SW620Exos we probed the phosphorylation status of 
cofilin, a downstream effector of RhoA/ROCK. This is an important assay as inactivation of cofilin via phos-
phorylation is a critical step in actin remodeling. As shown in Fig.8B, we found a clear and significant increase 
Figure 6. Analysis of protein content of exosomes derived from SW480 and SW620 cells. (A) Venn diagrams 
illustrating comparison of proteins detected in SW-Exos and Vesiclepedia-exosome dataset (on the left) and the 
Vesiclepedia-Top10 exosome proteins (on the right). (B) Volcano plot of the log2 Fold Change SW620Exos/
SW480Exos (x-axis) versus the -log10 BH corrected p-value (y-axis) of the 415 quantified proteins. The dashed 
lines correspond to 1.5-fold up and down (vertical lines), and an FDR value of 0.05 (horizontal line). The red 
points in the plot represent the 150 proteins that in the two exosome populations are differentially represented 
with statistical significance. (C) Heat map analysis of 150 proteins among three biological replicates between 
the SW480Exos and SW620Exos. The log10 value of the MS signal intensity is shown. (D) Cellular Component 
(CC) enrichment in SW480Exos and SW620Exos. In correspondence of each bars percentage of gene, fold 
enrichment and p value are reported; ns: non significant. (E) The protein network analysis performed using 
STRING v10.0 with a confidence level of 0.6 revealed the presence of RhoA partners among the proteins 
enriched in SW620Exos. The thickness of the connecting line represents the strength of the associations.
www.nature.com/scientificreports/
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in cofilin phosphorylation in response to SW620Exo treatment. Interestingly, we observed that the positive 
effect of SW620Exos on cofilin phosphorylation was reverted by co-treatment with Y-27632, a specific ROCK 
inhibitor (Fig. 8B).
Inhibition of RhoA/Rock signaling in recipient cells reverts the effects induced by SW620Exos. 
In line with the above result demonstrating the ability of Y-27632 to revert the SW620Exos-induced cofilin phos-
phorylation status, we found that inhibition of the RhoA signalling pathway by the ROCK inhibitor repressed 
the SW620Exo-induced morphological and structural effects in recipient cells. The confocal micrographs in 
Fig. 9 (upper panel) show that, when SW480 cells were co-treated with SW620Exos and Y-27632, the ability of 
exosomes to induce amoeboid transition and blebbing was completely reverted. Similarly, we observed that the 
co-treatment with SW620Exos and Y-27632 elicited in HUVECs the recovery of monolayer stability such as the 
VE-cadherin re-localization to the plasma membrane (Fig. 9, lower panel). Altogether, these results indicate that 
the effects induced by SW620Exos in both target cells are mediated by the activation of the RhoA/ROCK signa-
ling pathway.
Discussion
The presence of subclones with distinct genetic, epigenetic and phenotypic properties within a tumor has been 
widely described and represents one of the major obstacle for a highly efficient and successful prognosis and 
treatment of cancer32. This intratumor heterogeneity is probably due to both genomic instability and dynamicity 
of tumor microenvironment and is considered one of the main factors that can accelerate the tumor evolution 
influencing the metastatic potential and therapeutic resistance33, 34. Within the complex context of a heterogene-
ous tumor, sub-clones with distinct characteristics may establish positive interactions resulting in a phenotypic 
Figure 7. Thrombin is a key mediator of effects induced by SW620Exos in target cells. (A) Confocal 
micrographs show the ability of Thrombin to induce in SW480 cells the transition from an elongated to an 
amoeboid phenotype in a dose-dependent manner. Moreover, we found that the addition of Y-27632 was able to 
revert the effect induced by Thrombin, indicating the involvement of RhoA pathway. Except that for the Control 
(Ctrl: no treated cells), two representative fields are reported for each analysed condition. Cells were stained 
with Actin green (green) and nuclear counterstaining was performed using Hoescht (blue). (B) Percentage 
of SW480 blebbing cells obtained by counting 5 different fields for each reported condition. (C) Confocal 
micrographs show the ability of Thrombin to alter the HUVEC monolayer. As for SW480 cells, we found that 
the addition of Y-27632 was able to revert the effect induced by Thrombin. Except that for the Control (Ctrl: no 
treated cells), two representative fields are reported for each analysed condition. Cells were stained with Actin 
green (green) and nuclear counterstaining was performed using Hoescht (blue). (D) Dextran permeability assay 
of HUVEC monolayer after treatment with Thrombin and Thrombin + Y-27632. Values reported in the graphs 
are the mean ± SD of three independent experiments. Statistical significance was calculated as indicated by the 
horizontal lines; *p ≤ 0.05, **p ≤ 0.01; Thr: Thrombin.
www.nature.com/scientificreports/
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switch that promotes tumor growth and metastasis thus enhancing tumor progression35. Several studies clearly 
demonstrated that the inter-clonal cooperation between metastatic and non-metastatic cells can promote the 
metastatic cascade at both local and systemic levels36–38.
Recent accumulating evidence has demonstrated that within a heterogeneous tumor, tumor-derived exosomes 
(TDEs) play a relevant role as mediator of the inter-clonal collaborative cooperation35, 39. Interesting studies have 
reported that exosomes released by metastatic cells are able to induce the active transfer in non-metastatic cells 
of molecules strictly related to the aggressive phenotype (such as EGFRVIII and Met 72 tumor antigen) allowing 
the recipient cells to acquire abilities typical of metastatic phenotype12, 40. Moreover, by using the Cre-LoxP system 
and intravital imaging it was shown that less aggressive breast tumor cells exhibit increased migratory abilities 
after uptaking extracellular vesicles originating by highly aggressive cancer cells, indicating that TDEs can act as 
messengers of malignity15.
In the attempt to better define the molecular mechanisms underlying the ability of exosomes released by more 
aggressive cancer cells to modulate the plasticity of less aggressive sub-clones, we used a unique in vitro model of 
colon rectal cancer (CRC) progression, represented by two isogenic colon cancer cell lines because derived from 
primary (SW480 cells) and metastatic lesions (SW620 cells) of the same patient41. These cell lines represent two 
different stages of tumor development and can be considered representative of diverse sub-clones that constitute 
within a tumor the above mentioned condition of heterogeneity. Interestingly these two cell lines show different 
malignant properties42 and are characterized by markedly different morphologies: SW480 cells appear flat and 
with a spread mesenchymal-like morphology, while the metastatic SW620 cells display an amoeboid phenotype, 
characterized by rounded shape associated to membrane blebs20. Bleb formation has been described as the result 
of hydrostatic pressure generated in the cytoplasm by the contractile actomyosin21, 43, due to a dynamic remod-
eling of cell cytoskeleton. These morphologies are associated to two distinct modes of motility characteristic of 
individual tumor cells mentioned as mesenchymal and amoeboid migration. The ability of malignant tumor cells 
to switch from mesenchymal to amoeboid mode of movement (named mesenchymal to amoeboid transition - 
MAT) has been widely described44–46. This plasticity confers to cancer cells adaptive capacities to microenviron-
mental changes and is considered a fundamental requirement for tumor progression and metastasis12. Moreover, 
since conversely to the mesenchymal migration the amoeboid motility is independent from MMPs activity and 
integrin engagement47–49, the MAT has important consequences for therapeutic strategies limiting the effective-
ness of anticancer treatments based on the use of MMP inhibitors48, 50.
Figure 8. SW620Exos activate the RhoA/Rock pathway in recipient cells. (A) RhoA activity (on the left) and 
total RhoA (on the right) in SW480 cells and HUVECs treated for 6 hrs with 20 μg/ml of SW620Exos. Ctrl: cells 
without exosome treatment. Values are the mean ± SD of three independent experiments. Statistical significance 
was calculated vs ctrl: **p ≤ 0.01. (B) Upper panel reports representative immunoblots showing that treatment 
with SW620Exos (20 μg/ml) induced in SW480 cells the increase of p-cofilin levels, without affecting total 
cofilin levels. This effect was reverted by co-treating SW480 cells with the ROCK inhibitor Y-27632 (10 mM). 
GAPDH was used as loading control. Original uncropped WBs are reported in Figure S7C. The graph in the 
lower panel shows the ratio between p-cofilin/cofilin normalized to GAPDH. Values are the mean ± SD of three 
independent experiments. Statistical significance was calculated as indicated by the horizontal lines; *p ≤ 0.05.
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In the present study, we obtained evidences that through their exosomes, SW620 cells spread their metastatic 
abilities to less aggressive isogenic SW480 cells by inducing a phenotypic switch from elongated to rounded 
amoeboid phenotype associated to higher migratory and invasive capabilities. Notably, while the treatment with 
SW480Exos resulted, in homologous SW480 cells, in the maintaining of their elongated phenotype, SW620Exos 
strongly increased the amoeboid phenotype in the metastatic SW620 cells, suggesting the idea that SW620 cells 
sustain tumor progression both in a paracrine and autocrine manner.
Several recent studies have highlighted that clonal cooperation may facilitate metastasis not only by acting 
on tumor cell component but also by affecting the microenvironment properties through not mutually exclusive 
mechanisms35. Our data show that exosomes released by SW480 and SW620 cells are able to differentially affect 
the behavior of the endothelial component. We found that both exosome populations positively affected the abil-
ity of HUVECs to form vessel-like structures indicating their angiogenic property. Additionally, the SW620Exos 
had the exclusive capability to strongly alter the endothelium integrity by inducing an evident loss of the adherens 
junctions due to the VE-cadherin/catenin internalization, thus overcoming their angiogenic activity. These data 
suggested that exosomes released by tumor cells with different characteristics within a heterogeneous tumor mass 
could cooperatively act by promoting formation of new vessels and alteration of their integrity at the same time. 
These are both indispensable requirements for tumor cells intravasation and dissemination. This cooperative 
activity may accelerate tumor progression making simultaneous two progressing steps of metastatic cascade.
A pletora of published evidence demonstrates that both MAT and loss of VE-cadherin membrane localization 
are effects of RhoA activity46, 51. RhoA, with Rac1 and Cdc42, belongs to the Rho family of small GTPases that, 
by cycling between an active, GTP-bound form, and an inactive, GDP-bound form, regulate multiple cellular 
processes such as growth, survival, and cellular motility driving cytoskeletal reorganization. Several studies have 
clearly demonstrated that while Rac1 and Cdc42 induce respectively the formation of lamellipodia/membrane 
ruffles and filopodia52, RhoA activation regulates stress fiber formation and actomyosin contraction inducing 
round morphology and amoeboid motility46, 47, 53. For example, it was demonstrated that MDA-MB-231 cells 
expressing constitutively active Rho G14V mutant exhibited round/amoeboid morphology54.
Similarly, it has been reported that VE-cadherin disassembly and vascular permeability can be modulated by 
mechanical forces and tension exerted on cell adhesion by RhoA signaling inducing actomyosin contractility26, 55. 
Huang and colleagues have demonstrated that sevoflurane prevented LPS-induced rupture of HMVEC-L 
Figure 9. Inhibition of RhoA/Rock signaling in recipient cells reverts the effects induced by SW620Exos. 
Confocal micrographs show the ability of Y-27632 (10 mM) to revert morphological effects induced by 
SW620Exos (20 µg/ml) in both SW480 cells and HUVECs. Cells were stained with Actin green (green) and 
nuclear counterstaining was performed using Hoescht (blue). HUVECs were also probed with anti-VE cadherin 
(red); Ctrl (Control): no treated cells.
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monolayers by suppressing the VE-cadherin internalization mediated by activation of RhoA/ROCK signaling 
pathway51. Interestingly, Gene Ontology and STRING analyses of SWATH-based quantitative proteomic data 
obtained by comparing SW480Exos and SW620Exos highlighted that among the proteins specifically enriched in 
SW620Exos (i) the most represented GO category was that of cytoskeletal associated proteins and (ii) there were 
seven RhoA interactors. Previous comparative proteomic studies carried out on exosomes derived from SW480 
and SW620 cells reported that the major differences between the two nanovesicle populations were related to 
proteins involved in signaling or with angiogenic properties56, 57. The discordance with our results is probably 
due to the different proteomic strategies used. Our MS data was obtained by applying a SWATH method, a tech-
nique in which data-independent acquisition is coupled with peptide spectral library match, and that allows 
to do label-free quantification in an MRM-like manner. Several recent studies have widely demonstrated that 
SWATH-MS, combining the strengths of shotgun in terms of proteome coverage, and quantification accuracy 
and precision of SRM technologies, provides valuable quantification on proteome scale58, 59. In light of these con-
siderations, we think that our proteomic results, although limited in terms of proteome coverage in comparison 
to published data, are robust under a quantitative point of view and more suitable for a comparative proteomic 
study. As discussed above, in the dataset of proteins over-represented in SW620Exos we found seven RhoA inter-
actors, and among them RacGAP1 and Thrombin (F2) are described in literature as directly responsible for RhoA 
activation27, 28.
RacGAP1 (Rac GTPase-activating protein) is a Rho GTPase-activating protein that plays a key role in con-
trolling various cellular phenomena including cytokinesis, transformation, invasive migration and metastasis25. 
RacGAP1 has the ability to locally suppress Rac1 activity and activate RhoA at the cell front promoting the exten-
sion of membrane protrusions and invasive migration, when bound to IQGAP1 (present in both exosome popu-
lations; see Supplementary Tables, Sheet “Identification MS data”)25. The balance between levels of activated Rac 
and Rho determines the mesenchymal or amoeboid mode of cell motility, and mutual antagonism between Rac 
and Rho contributes to the maintenance of different modes of cell motility60. Therefore, it was notable to find this 
protein enriched 10-fold in SW620Exos. Moreover, Zhang and colleagues demonstrated that in endothelial cells 
RacGAP1, by activating RhoA, induced junction breakdown with consequent increase of permeability promoting 
melanoma cells transendothelial migration61.
F2 (Thrombin) is a multifunctional serine protease that converts fibrinogen to fibrin in the blood coagulation 
cascade and is a potent activator of platelet aggregation. Several studies performed in endothelial and cancer cells 
have shown that thrombin by PAR signaling induced morphological changes in actin organization through RhoA 
activation, regulating angiogenesis and cancer progression28–30, 62. We demonstrate here, for the first time, that 
Thrombin, which we found over-represented in SW620Exos, can induce elongated non-aggressive cancer cells 
to acquire an amoeboid morphology through the involvement of the RhoA/ROCK pathway. In line with these 
observations, we found that treatment of both cancer and endothelial cells with SW620Exos induced a significant 
RhoA activation in comparison to the control condition. Moreover, the ability of a specific ROCK inhibitor to 
revert in both types of recipient cells the effects induced by SW620Exo treatment strongly underlined the central 
role of RhoA activation in this cellular cross-talk system.
Our data clearly demonstrate that exosomes can be considered key elements in the context of tumor heter-
ogeneity, because they regulate the collaborative interactions established among sub-clones of cancer cells with 
different metastatic potentials. In other words, exosomes from more aggressive cells may be able to accelerate 
tumor progression within a heterogeneous primary tumor, by activating the RhoA/ROCK signaling pathway in 
cells that uptake them. This process may be able to accelerate tumor progression acting on two distinct levels: 1) 
by inducing the phenotypic switch of less aggressive tumor cells by transferring the functional properties associ-
ated to metastatic behavior; 2) by affecting endothelial stability for the loss of VE-cadherin membrane localization 
with consequent endothelial hyperpermeabilty (Fig. 10).
In conclusion, our results indicated that, in a heterogeneous context, exosomes released by aggressive 
sub-clones contribute to accelerate tumor progression by spreading malignant properties that affect both the 
tumor cell plasticity and endothelial cell behavior. Thus, TDEs might positively regulate metastasis not only by 
favoring the development of pre-metastatic niches that allow the tumor growth in secondary sites14, but also by 
inducing a rush of the initial steps of the metastatic cascade already in primary tumor site where heterogeneous 
sub-clones co-exist.
Materials
Cell culture and reagents. SW480 and SW620 cells (ATCC), were grown in RPMI 1640 (Euroclone UK) 
supplemented with 10% fetal bovine serum (FBS; Euroclone UK), 2mM L-glutamine (Euroclone UK), 100 U/
ml penicillin and 100 µg/ml streptomycin. Caco2 cells (ATCC), were cultured in DMEM (Gibco USA) supple-
mented with 10% FBS (FBS; Euroclone UK), 2mM L-glutamine (Euroclone UK), 100 U/ml penicillin and 100 µg/
ml streptomycin. Human umbilical vein endothelial cells (HUVEC, Lonza, Clonetics, Verviers, Belgium) were 
cultured in endothelial growth medium (EGM) according to supplier’s information. SW480 and SW620 cells were 
maintained at 80% of confluence to recover exosomes. Cells were grown at 37° in a 5% CO2 atmosphere. Where 
described, SW480 cells were treated for six hours with 0.2 U/ml or 0.5 U/ml of Thrombin. To inhibit ROCK 1/2, 
cells were treated with 10 µM of Y-27632 ROCK inhibitor (Selleckchem) for 6 hrs. Unless otherwise indicated, all 
chemicals were from Sigma (St. Louis, MO).
Scanning electron microscopy (SEM). SW480 and SW620 cells were seeded and cultured for 48 h as 
described above. Following removal of medium, cells were fixed with 2.5% glutaraldehyde in 100 mM PBS for 
20 min. After dehydration (100% ethanol), the samples were critical point dried (Critical Point Dryer Quorum 
K8509), gold sputtered (Agar Sputter Coater) and analyzed using a Zeiss, EVO HD15 scanning electron 
microscope.
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Exosome isolation using OptiPrep™ density gradient medium. Exosomes released by SW480 
(SW480 Exos) and SW620 (SW620 Exos) cells during a 24 hrs culture period, were collected from conditioned 
culture medium supplemented with 10% FBS previously ultracentrifuged (vesicles free media) by different cen-
trifugations, as previously described63. Briefly, cells and debris were eliminated by centrifugation at 2,800 g for 
10 min; in order to discard large EVs from culture medium, the supernatant was then centrifuged at 10,000 g for 
30 min. For isolation of exosomes, the supernatant remaining after the 10,000 g spin was subsequently centrifuged 
at 100,000 g for 1 hr.
To further purify exosomes, OptiPrep™ density gradient centrifugation of the 100,000 g pellets was carried 
out63. Briefly 60%, 50%, 40%, 30%, 25%, 15%, 10% and 5% solutions were made by diluting a stock solution of 
OptiPrep™ (60% aqueous iodixanol) in 0.25 M Sucrose/0.9 M NaCl/120 mM HEPES, pH 7.4. The 100,000 g pellet 
was mixed in the bottom layer and the solutions carefully layered. Centrifugation was performed at 100,000 g for 
3 hrs and 50 min at 4 °C with a SW28 Beckman rotor. Eight individual fractions were collected, washed with PBS, 
and then centrifuged at 100,000 g for 1 h at 4 °C; the pellet from each fraction was then suspended in PBS or lysis 
buffer. Exosome’s protein content was determined with the Bradford method (Pierce, Rockford, IL, USA).
Labeling and internalization of exosomes. SW480Exos and SW620Exos were labeled with PKH26, 
according to the manufacturer’s instructions. Briefly, exosomes were incubated with PKH26 for 10 min at room 
temperature. washed in PBS, centrifuged, resuspended in low serum medium and incubated with either HUVECs, 
or SW480 or SW620 cells for 3 hrs at 37 °C. After incubation, cells were processed as previously described64 and 
stained with ActinGreenTM 488 Ready ProbesR Reagent (Life Technologies, USA) that binds F-actin with high 
affinity. Nuclei were stained with Hoechst (Molecular Probes, Life Technologies, USA). Microscopy was per-
formed using a fluorescence microscope (Nikon Confocal A1). Images were acquired at resolution of 1024 × 1024 
and any downstream processing or averaging that enhances the resolution was applied.
Immunofluorescent microscopy. HUVECs (grown to confluence on coverslips coated with type I col-
lagen - Calbiochem, Darmstadt, Germany), SW480 and SW620 cells (grown to sub-confluence on uncoated 
coverslip) were treated or not with SW480Exos or SW620Exos (20 μg/ml) for 3 and 6 hrs, Thrombin (0.2 U/ml 
and 0.5 U/ml) for 6 and 1 hrs and, where reported, co-treated with Y-27632 inhibitor. Caco2 cells (grown to 
sub-confluence on coverslips coated with type I collagen - Calbiochem, Darmstadt, Germany) were treated or not 
with SW480Exos and SW620Exo (20 μg/ml) for 6 hrs.
After treatments, cells were processed as described64. Antibodies for VE cadherin, β-catenin and p120-catenin 
(1:100; Santa Cruz Biotechnology, Santa Cruz CA, USA) were used; fuorescently labeled secondary antibodies 
Alexa Fluor 594 (1:100, Molecular Probes Eugene, Oregon USA) were used.
Actin filaments were stained with ActinGreenTM 488 as above reported. Nuclei were counterstained with 
Hoechst (Molecular Probes, Life Technologies, USA). The samples were analyzed by using the fluorescence 
microscope Nikon Confocal A1. Image were acquired at resolution of 1024 × 1024 and any downstream process-
ing or averaging that enhances the resolution was applied.
RNA extraction and real-time PCR. HUVECs were grown to confluence in 6-well plates and incubated 
for 6 hrs with SW480Exos or SW620Exos (5–10–20 µg/ml); SW480 and SW620 cells were grown to confluence 
in 12-well plates for 48 hrs. For quantitative SYBER®Green Real Time PCR, reactions were carried out in a total 
volume of 20 μl containing 2 × SYBR®Green I Master Mix (Applied Biosystems, Foster City, CA, USA), 2 μl cDNA 
Figure 10. Proposed model of the morphological and molecular effects induced in recipient cells by metastatic 
cell derived-exosomes.
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and 300 nM forward and reverse primers. Primers sequence were: GAPDH (5′ATGGGGAAGGTGAAGGTCG3′, 
5 ′GGGTCATTGATGGCAACAATAT3 ′),  VE-Cadherin (5 ′GATCAAGTCAAGCGTGAGTCG3 ′ ; 
5 ′ AG C C TC TC A ATG G C G A AC AC 3 ′ )  and  T h rombi n  ( 5 ′ G C AC AG C C AG C ATG TG T TC C ′ , 
5′CACATCCGTAGCCGTGGAG3′).
Real-time PCR was performed in duplicate for each data point. Relative changes in gene expression between 
control and treated samples were determined with the ΔΔCt method. Changes in the target mRNA content 
relative to GAPDH were determined using the comparative Ct method. Each sample was run in triplicate and Ct 
means are used for the analysis.
Western Blot (WB). HUVEC, SW480, SW620 cell lysates or exosome proteins (15 or 30 μg per lane) were 
separated using 4–12% Novex Bis-Tris SDS-acrylamide gels (Invitrogen, Life Technologies, USA), transferred on 
Nitrocellulose membranes (Invitrogen, Life Technologies, USA), and immunoblotted with the following primary 
antibodies: CD63, CD81, Calnexin, Cofillin, phospho-Cofillin, VE-cadherin (Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA, USA). All secondary antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA). Chemiluminescence was detected using AmershamTM ECLTM 
Western Blotting Detection Reagents (GE Healhtcare, UK). The blots were scanned and densitometric analysis 
performed by Image J software (http://rsbweb.nih.gov/ij/).
Migration and invasion assay. In vitro cell migration and invasion activities were evaluated in transwell 
chambers as previously described64. Briefly, SW480 and SW620 cells (280 × 103/ml) suspended in serum-free 
RPMI 1640 medium supplemented with 0.1% BSA, with or without increasing amount of exosomes (20–50 µg/
ml) were seeded in transwells with 8 μm pore filter coated with collagen (for motility assay) or matrigel (for inva-
sion assay) and exposed to medium supplemented with 10% of FBS (chemoattractant) for 72 hrs at 37 °C in 5% 
CO2. Caco2 cells (20 × 103/ml) suspended in serum-free DMEM medium supplemented with 0.1% BSA, with or 
without 20 µg/ml of SW480 and SW620 exosomes were seeded in transwells with 8 μm pore filter coated with col-
lagen (for motility assay) or matrigel (for invasion assay) and exposed to medium supplemented with 10% of FBS 
(chemoattractant) for 48 hrs (for motility assay) and 72 hrs (for invasion assay) at 37 °C in 5% CO2. At the end of 
the assay, after removing non-migrating cells by scraping from the top of the filter, each filter was fixed in ethanol, 
stained with Diff-Quick (Medion Diagnostics GmbH, Dudingen, Switzerland) and cells were observed by a light 
microscope at 400x magnification. Each assay was performed in triplicate; migrating/invading cells were counted 
in at least five high power fields per well by using Image J.
Dextran permeability assay. HUVECs were seeded onto collagen-coated Transwell inserts (0.4 μm pore 
size; Corning) at a cell density of 1.5 × 105 cells. After 24 hrs, confluent HUVECs were treated for 6 hrs with 
20 μg/ml SW480Exos or SW620Exos, or for 1 h with 0.2 U/ml of Thrombin and then FITC-dextran (2 mg/ml) 
was added to monolayer (upper chamber) for 1 hrs. FITC-dextran present in the lower chamber was assayed at 
495 nm by using GloMax Multimicroplate reader (Promega, Mannheim, Germany). Fluorescence intensity meas-
urements were expressed as Relative Permeability by calculating the fold increase over the basal permeability of 
untreated monolayer (control).
Proteomic analyses: sample preparation, SWATH-MS and data analysis. Exosomes were dis-
solved in 50% TFE/PBS and subjected to tryptic digestion. Three biological replicates of each sample were pre-
pared and subjected to DDA and SWATH analysis. A deep description of the tryptic digestion and DDA/SWATH 
procedures are reported in Supplementary Material and Methods. DDA raw files were combined and searched 
against the human database to generate the reference spectral library, which was used for SWATH data processing 
and quantification. The protein list with FDR lower than 5% generated by analyzing SWATH data with PeakView 
2.2, was exported to MarkerView 1.2.1 for statistical data analysis using a pairwise t-test. Three biological repli-
cates were performed for each exosome populations and Fold Change (FC) SW620Exos vs SW480Exos thresholds 
at 1.5 with an adjusted p-value inferior to 0.05 were used to consider a protein up or down-regulated. The p-values 
were adjusted using a Benjamini-Hochberg (BH) correction and q-value. The FC was transformed using the log2 
function, so that the data is centered on zero, while the BH corrected p-value was −log10 transformed for vol-
cano plot scaling. The GO analysis of SW-Exo protein content was performed using the stand-alone enrichment 
analysis tool FunRich (Functional Enrichment analysis tool; http://www.funrich.org)23. The molecular interaction 
network among the significantly enriched proteins in SW620Exos was analyzed by STRING (Search Tool for 
the Retrieval of Interacting Genes/Proteins) using the confidence level 0.6. Of note, not all proteins significantly 
enriched in SW620Exos are included in the presented protein network since disconnected nodes are hidden for 
better visualizing molecular interaction network.
RhoA Activation Assay. RhoA activation was quantified by measuring the amounts of RhoA-GTP via 
the G-LISA RhoA Activation Biochem assay kit (BK150 Cytoskeleton, Inc, Denver, CO), an enzyme-linked 
immunosorbent assay (ELISA)-based. The total cellular lysates from the SW480 cells and HUVECs treated with 
20 μg/ml of SW620Exos or vehicle for 6 hrs were used to measure the RhoA activity. The assay was performed 
according to the manufacturer’s instructions. Active RhoA-GTP from lysates is bound to the Rho-GTP binding 
domain of a Rho effector immobilized in the 96-well plate, whereas inactive Rho-GDP is removed during the 
washing step. RhoA-GTP is subsequently detected by primary anti-RhoA antibody and horseradish peroxidase 
(HRP)-conjugated secondary antibody. Quantitation of total RhoA was determined by using a RhoA ELISA kit 
(BK124 Cytoskeleton, Inc, Denver, CO). The HRP reaction signal was quantified by measuring absorbance at 
490 nm and recorded using a microplate spectrophotometer (Model 680XR, BioRad). Each sample reading was 
normalized against the reading of the blank buffer65. Each test group was assayed in triplicate.
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Statistics. Data were expressed as means ± SEMs of the indicated number of experiments. Statistical analysis 
was performed by using a unpaired Student’s t test. Differences were considered to be significant when p-values 
were ≤than 0.05.
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